AN2 Therapeutics, Inc.

ANTXNASDAQHealthcare● Active

$4.65

$-0.09(-1.90%)

Market Cap$127419412

P/E Ratio—

52W High$6.91

52W Low$1

Avg Volume298K

Open$4.74

Beta-0.98

Overview

AN2 Therapeutics, Inc. (ANTX) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

ANTX · cash on hand · updated Dec 31, 2025

Core cash position

as of Dec 31, 2025

Cash & Short-Term Investments (CCE + ST Investments)

$58.0M▼ -30.6% vs prior year

FY · as of Dec 31, 2025 · Reported in USD

Cash & Cash Equiv. (CCE)

$19.9M

cashAndCashEquivalents

Short-Term Investments

$38.1M

shortTermInvestments

YoY Change vs Prior Year

-30.6%

vs prior fiscal year

Latest Quarter

$85.3M

Q1 2026

Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash vs Debt · Balance Sheet Health

Cash & ST Investments$58.0MCash on Hand

Total Debt$0Total Debt

Net Cash / Net Debt+$58.0MNet Cash Position

Cash vs Debt Ratio

Cash 100%AN2 Therapeutics, Inc. cash as % of market cap: 45.52%% · MCap $0BDebt 0%

AN2 Therapeutics, Inc. has a net cash position of $58.0M, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$58.0M − $0 = +$58.0M

Cash on hand history

annual cash on hand trend · Cash & Short-Term Investments

YoY Increase

YoY Decrease

Latest Year

ANTX annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

ANTX cash & short-term investments history

DatePeriodCash & ST InvestmentsYoY Change

Dec 31, 2025LatestFY$58.0M-30.6%

Dec 31, 2024FY$83.6M-22.1%

Dec 31, 2023FY$107.3M+11.7%

Dec 31, 2022FY$96.1M+64.0%

Dec 31, 2021FY$58.6M+1338.7%

ANTX cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

ANTX vs peers · cash on hand

#CompanyCash & ST Inv.Market CapCash/MCapRelative

UnitedHealth Group Incorporated

Eli Lilly and Company

AN2 Therapeutics, Inc.YOU

ANTX

$58.0M$130M44.5%

Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

AN2 Therapeutics, Inc. (ANTX) cash on hand as of December 31, 2025 is $58.0M, comprising $19.9M in cash and cash equivalents (CCE) plus $38.1M in short-term investments — reported as AN2 Therapeutics, Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as AN2 Therapeutics, Inc. cash reserves or cash position.

AN2 Therapeutics, Inc. annual cash on hand history shows decreased -30.6% in 2025: decreased -30.6% in 2025. AN2 Therapeutics, Inc. cash reserves in 2025 reflect the company's capital allocation strategy.

AN2 Therapeutics, Inc. carries total debt of $0 against cash of $58.0M, resulting in a net cash position of +$58.0M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.

Financial statements Free cash flow Net income Revenue Market cap P/E ratio Earnings Price history

Frequently asked questions

ANTX cash on hand · 5 questions

As of December 31, 2025, AN2 Therapeutics, Inc. (ANTX) has $58,001,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $19,941,000 in cash and cash equivalents (CCE) plus $38,060,000 in short-term investments. Latest quarter (March 31, 2026): $85,288,000. Data sourced from the annual 10-K filing via FMP.

ANTX cash on handANTX cash reservesANTX cash 2025how much cash does ANTX have

▸ Source: FMP /balance-sheet-statement · US GAAP · AN2 Therapeutics, Inc. · AN2 Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025